| Literature DB >> 34781744 |
Aidan Dmitriev1, Xingru Chen1, Elyse Paluscio1, Amelia C Stephens1, Srijon K Banerjee1, Nicholas P Vitko2, Anthony R Richardson1.
Abstract
Staphylococcus aureus is the most pathogenic member of the Staphylococcaceae. While it acquired an arsenal of canonical virulence determinants that mediate pathogenicity, it has also metabolically adapted to thrive at sites of inflammation. Notably, it has evolved to grow in the presence of nitric oxide (NO·). To this end, we note that the Rex regulon, composed of genes encoding dehydrogenases, metabolite transporters, and regulators, is much larger in S. aureus than other Staphylococcus species. Here, we demonstrate that this expanded Rex regulon is necessary and sufficient for NO· resistance. Preventing its expression results in NO· sensitivity, and the closely related species, Staphylococcus simiae, also possesses an expanded Rex regulon and exhibits NO· resistance. We hypothesize that the expanded Rex regulon initially evolved to provide efficient anaerobic metabolism but that S. aureus has co-opted this feature to thrive at sites of inflammation where respiration is limited. One distinguishing feature of the Rex regulon in S. aureus is that it contains the srrAB two-component system. Here, we show that Rex blocks the ability of SrrA to auto-induce the operon, thereby preventing maximal SrrAB expression. This results in NO·-responsive srrAB expression in S. aureus but not in other staphylococci. Consequently, higher expression of cytochromes and NO· detoxification are also observed in S. aureus alone, allowing for continued respiration at NO· concentrations beyond that of S. simiae. We therefore contend that the intersection of the Rex and SrrAB regulons represents an evolutionary event that allowed S. aureus to metabolically adapt to host inflammatory radicals during infection. IMPORTANCE Pathogens must evolve virulence potential to improve transmission to new hosts as well as evolve metabolically to thrive within their current host. Staphylococcus aureus has achieved both of these, and here, we show that one such metabolic adaptation was the expansion of the Rex regulon. First, it affords S. aureus with efficient respiration-independent growth critical to surviving the inflammatory environment replete with respiration-inhibiting immune radicals. Second, it includes the srrAB operon encoding a two-component system critical to maximizing respiratory capacity in the face of host nitric oxide (NO·), a potent respiratory inhibitor. This second facet is only apparent in S. aureus and not in other closely related species. Thus, evolutionarily, it must have occurred relatively recently. The intertwining of the Rex and SrrAB regulons represents an important evolutionary event that affords S. aureus the metabolic flexibility required to thrive within inflamed tissue and cause disease.Entities:
Keywords: Staphylococcus aureus; coagulase-negative staphylococci; fermentation; immune radicals; metabolic evolution; metabolism; nitric oxide; redox signaling
Mesh:
Substances:
Year: 2021 PMID: 34781744 PMCID: PMC8593685 DOI: 10.1128/mBio.02188-21
Source DB: PubMed Journal: mBio Impact factor: 7.867
FIG 1An expanded rex regulon is necessary and sufficient for staphylococcal NO· resistance. (A) Number of putative Rex-regulated genes from closely related staphylococcal species as determined by the presence or absence of a Rex binding sites in the promoter regions. (B) Representative growth curve of three replicates demonstrating that both S. aureus and S. simiae exhibit NO· resistance compared with S. epidermidis that lacks the expanded Rex regulon. NO· was administered as a mixture of 10 mM NOC and 12:1 mM DETA-NO. (C) Overexpression of Rex from the lgt promoter limits S. aureus growth in the presence but not the absence of NO·. Representative growth curve of three independent replicates using 10 mM DETA-NO as the NO· donor. (D) Overexpression of Rex from the lgt promoter limits growth anaerobically.
FIG 2S. aureus srrAB alone responds to exogenous NO·. (A) Alignment of srrAB promoter regions from closely related staphylococcal species. Putative Rex (TGTGAW6TCACA) and SrrA (AAATAN4TTTAT) binding sights are outlined in red and green, respectively. (B) Expression of GFP driven by the S. aureus srrAB promoter responds to NO· (10 mM DETA-NO administered at OD660 of 0.2), whereas srrAB promoters from other species do not. (C) Quantification of p-GFP induction 30 min following NO· challenge from closely related staphylococcal species. Data were analyzed via one-way analysis of variance (ANOVA) with Dunnett’s correction for multiple comparisons (****, P ≤ 0.0001).
FIG 3qRT-PCR analyses of the induction of srrAB and SrrAB-regulated genes in S. aureus and S. simiae upon exposure to exogenous NO·. (A) srrA transcript level analyzed via qRT-PCR and normalized to that of rpoD in wild-type (WT) S. aureus and indicated isogenic mutants in the absence of exogenous NO·; n = 3. Statistical significance was established via a one-way ANOVA with Dunnett’s posttest (***, P ≤ 0.0001). (B and C) Fold induction of indicated genes 15 min (B) or 60 min (C) following NO· exposures (administered as 10 mM DETA-NO; n = 3) relative to untreated expression levels. Expression levels were normalized to that of rpoD, and induction levels were compared between species for a given gene/time point using Student's t test using the Holm-Sidak method (***, P ≤ 0.0001; **, P ≤ 0.01; *, P ≤ 0.05).
FIG 4S. aureus alone exhibits elevated respiratory capacity and NO· detoxification upon exposure to exogenous NO·. (A) NO· consumption rate by cells either prestimulated with NO· (10 mM DETA-NO for 1 h) or unstimulated. (B) Oxygen consumption rate before or after NO· exposure (10 mM DETA-NO for 1 h) using a Clark-type electrode. Oxygen consumption was initiated by addition of 0.01% glucose to washed and resuspended cells (OD660, 1.0) (C) Concentration of NO· remaining in suspension when cells resume respiration. Cells were either prestimulated with NO· (10 mM DETA/NO for 1 h) or unstimulated. Statistical comparisons were carried out using a one-way ANOVA with Tukey’s posttest (****, P ≤ 0.0001; **, P ≤ 0.01; *, P ≤ 0.05).
Strains and plasmids used in this study
| Strain or plasmid | Genotype | Source or reference |
|---|---|---|
| Strains | ||
| | Methicillin-resistant clinical isolate; laboratory strain | Laboratory strain |
| | Methicillin-resistant clinical isolate; laboratory strain | Laboratory strain |
| | CCM 7213 | Laboratory strain |
| | RP62A | Laboratory strain |
| | ATCC 15305 | Laboratory strain |
| | JCSC1435 | Laboratory strain |
| AR1593 | COL + pAD02 | This study |
| AR1612 | COL + pEP06 | This study |
| AR1606 | COL + pEP05 | This study |
| AR1600 | COL + pEP04 | This study |
| AR1569 | COL + pAD01 | This study |
| AR0352 | COL Δrex::Knr |
|
| AR1626 | COL ΔsrrB::Err (Φ11 NE588) | This study |
| AR1630 | COL Δrex::Knr, ΔsrrB::Err (Φ11 NE588) | This study |
| AR1315 | COL + pOS1-Plgt | This study |
| AR1408 | COL + pNV55 | This study |
| NE588 | SAUSA300_1441::Tn |
|
| Plasmids | ||
| pBT2ts |
| |
| pBTK | 1.4 kb |
|
| pJF119 | CAT allele (Cmr) replacement of ApaI/XhoI Err region of promoterless GFP fusion vector pCN52 | |
| pAD01 | This study | |
| pAD02 | This study | |
| pEP04 | This study | |
| pEP05 | This study | |
| pEP06 | This study | |
| pOS1-P |
| |
| pNV55 | This study |
Primers used in this study
| Primer | Sequence | Use |
|---|---|---|
| srrAB-RT.2A |
| qRT-PCR |
| srrAB-RT.2B |
| qRT-PCR |
| cydA-RT.1A |
| qRT-PCR |
| cydA-RT.1B |
| qRT-PCR |
| qoxB-RT.3A |
| qRT-PCR |
| qoxB-RT.3B |
| qRT-PCR |
| hmp-RT.1A |
| qRT-PCR |
| hmp-RT.1B |
| qRT-PCR |
| rpoD-RT.1A |
| qRT-PCR |
| rpoD-RT.1B |
| qRT-PCR |
| srrA-Sim-RT.1A |
| qRT-PCR |
| srrA-Sim-RT.1B |
| qRT-PCR |
| cydA-Sim-RT.1A |
| qRT-PCR |
| cydA-Sim-RT.1B |
| qRT-PCR |
| qoxB-Sim-RT.3A |
| qRT-PCR |
| qoxB-Sim-RT.3B |
| qRT-PCR |
| hmp-Sim-RT.3A |
| qRT-PCR |
| hmp-Sim-RT.3B |
| qRT-PCR |
| rpoD-Sim-RT.1A |
| qRT-PCR |
| rpoD-Sim-RT.1B |
| qRT-PCR |
| COL-srrA.1A |
| Construction of pAD02 |
| COL-srrA.1B |
| Construction of pAD02 |
| Sapro-srrA.1A |
| Construction of pEP04 |
| Sapro-srrA.1B |
| Construction of pEP04 |
| Haemo-srrA.1A |
| Construction of pAD01 |
| Haemo-srrA.1B |
| Construction of pAD01 |
| RP62A-srrA.1A |
| Construction of pEP05 |
| RP62A-srrA.1B |
| Construction of pEP05 |
| Sim-srrA.1A |
| Construction of pEP06 |
| Sim-srrA.1B |
| Construction of pEP06 |